Ivana Magovcevic-Liebisch Biography and Net Worth

Ivana is an accomplished pharmaceutical and biotechnology executive focused on corporate excellence and execution. She has over 25 years of senior management experience in financing, strategic partnerships, M&A, clinical development, regulatory affairs, commercialization, legal and IP strategies, and preparation and execution of operating plans. Prior to Vigil, Ivana was Executive Vice President (EVP) and Chief Business Officer at Ipsen where she was responsible for fueling the pipeline through external innovation and led the External Innovation, Business Development and Alliance Management functions. Prior to Ipsen, Ivana was EVP, Chief Strategy and Corporate Development Officer at Axcella Health, Senior VP (SVP) and Head of Global Business Development for the specialty drug business at Teva Pharmaceutical Industries Ltd. She previously worked at Dyax Corp in management roles of increasing scope and responsibility, including EVP and Chief Operating Officer where she launched the company’s first drug, Kalbitor® for an orphan indication, Hereditary Angioedema, and at Transkaryotic Therapies, Inc. Ivana serves as a member of the Board of Directors for Acrivion Therapeutics, Inc. and Quanterix Corporation. Ivana received a BA in Biology and Chemistry from Wheaton College, holds a PhD in Genetics from Harvard University and received her JD in High Technology law from Suffolk University Law School.